IVAC Economics & Finance Team Highlights Immunization Financing Gap

 

 

VACCINE ACCESS DIGEST | FEBRUARY 2023

 

NEWS & ANNOUNCEMENTS
 

IVAC Economics & Finance Team Highlights Immunization Financing Gap 

IVAC health economists, led by Bryan Patenaude, ScD, have recently published several papers focused on the cost of procuring and delivering life-saving vaccines to increase coverage and meet Immunization Agenda 2030 targets. The first paper found a funding gap of US$38.4B for 16 vaccines among 94 LMICs between 2011–2030, more than 80% of which is attributable to service delivery costs. The second paper estimates that it will cost US$269.8B to reach IA2030 goals for coverage against 14 pathogens in 194 countries between 2021–2030, and low-income countries would need to increase their immunization expenditures sixfold to fully self-finance immunization programs.

To learn more, tune into the Health Affairs podcast to hear IVAC Research Associate Salin Sriudomporn, MHS elaborate on the immunization finance gap.
?️ Listen to Podcast
 
!--

-->
Introducing the Immunization Agenda (IA2030) Scorecard

The IA2030 Scorecard illustrates global progress toward the monitoring and evaluation indicators of the IA2030 Framework for Action Impact Goals: Prevent Disease, Promote Equity, and Build Strong Programmes. The scorecard is a collaborative effort led by USAID MOMENTUM Country and Global Leadership working in partnership with the IA2030 Working Groups on Monitoring & Evaluation and Communications & Advocacy, with oversight from the IA2030 Secretariat and Coordinating Committee.
Tutorial introducing the IA230 Scorecard
Webinar: To better understand how the new IA2030 scorecard can help you monitor and communicate about progress and shortcomings related to immunization targets, watch Agenda-Setting with Evidence and Context: Using the Immunization Agenda 2030 Scorecard with MOMENTUM Country and Global Leadership and the Boost CommunityDownload the accompanying slides here.
? Explore IA2030 Scorecard
 

VIRA Chatbot Wins Anthem Award

IVAC’s VIRA chatbot recently received an Anthem Award for its innovative approach to communicating about the COVID-19 vaccine. VIRA is an AI-based chatbot, developed with IBM during the peak of the COVID-19 pandemic, that provides clear and concise answers to questions about the COVID-19 vaccine in both English and Spanish. The Anthem Awards recognized VIRA with a Silver Award in its Innovation category, which recognizes new products and services that boost awareness about health issues.  

The team behind VIRA also recently published a paper assessing the chatbot’s usability and credibility among young adults and health workers in the United States. Their results, published in JMIR Human Factors, provided multidimensional feedback and offered tangible steps to improve the product’s visual design. 
 
!--

-->

Measles and Rubella: A Timely Update for Pediatricians

Check out IVAC's executive director, William Moss, MD, present key clinical and epidemiological aspects of measles and rubella in a recent webinar hosted by the International Pediatric Association.

 
 

Want to stay up-to-date with the latest vaccine news?

Connect with us on LinkedIn where we highlight current vaccine research, initiatives, and updates. Let's keep the important conversations going!
 

RECENT PUBLICATIONS
 

A qualitative inquiry in understanding trusted media sources to reduce vaccine hesitancy among Kenyans 
By Berhaun Fesshaye, Clarice Lee, Alicia Paul, Eleonor Zavala, Prachi Singh, Ruth Karron, and Rupali Limaye

National health authorities in Kenya have recommended the use of the COVID-19 vaccine in pregnancy and lactation, but vaccine uptake among pregnant and lactating women has been low. A recent study published in Frontiers examines the health information sources used by pregnant and lactating women, healthcare workers, community members (male relatives, male neighbors, and gatekeepers), and policymakers in Kenya to explore how these sources influence vaccine decision-making. To increase vaccine confidence and uptake, it is imperative to ensure that COVID-19 vaccine information provided by both traditional and social media sources is accurate and timely.
 

Epidemiology of human parainfluenza virus type 3 and respiratory syncytial virus infections in the time of coronavirus disease 2019: Findings from a household cohort in Maryland (COVID-19) 
Authors include Marissa Hetrich, Maria Deloria Knoll, and Ruth Karron

In a study published in Clinical Infectious Diseases, the SARS-CoV-2 Epidemiology And Response in Children (SEARCh) team presented results from their longitudinal household cohort surveillance study. In this study, they examined SARS-CoV-2 epidemiology among Maryland children aged 0–4 years and their household members. Findings revealed that among children aged 0–4 years, incidence rates for symptomatic human parainfluenza type 3 and respiratory syncytial virus infection were four times higher than for SARS-CoV-2 during epidemic periods for each virus.
 

Twitter
Facebook
Website
LinkedIn
Copyright © 2023 International Vaccine Access Center, All rights reserved.
You are receiving this email because you opted in via our website.

Our mailing address is:
International Vaccine Access Center
415 N Washington St # 5
Baltimore, MD 21231-1121

Add us to your address book


Email Marketing Powered by Mailchimp


image    image